{"id":71287,"date":"2025-09-18T10:01:00","date_gmt":"2025-09-18T10:01:00","guid":{"rendered":"https:\/\/kanboapp.com\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/"},"modified":"2025-09-18T10:01:00","modified_gmt":"2025-09-18T10:01:00","slug":"navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges","status":"publish","type":"page","link":"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/","title":{"rendered":"Navigating the Complexities of Risk Visibility: Transforming Pharmaceutical Risk Management Amidst Regulatory Competitive and Technological Challenges"},"content":{"rendered":"<style> @media(min-width:1728px) { .tytulek{font-size:34px!important;max-width: 1200px!important;} .sekcja-tekst { margin-left: 40px!important; margin-right: 40px!important;} .artykul{margin-bottom:120px!important; margin-top:120px!important;} .menu-lewe a:hover { background:#E9F4FE!important; font-weight:600!important; font-size:16px!important; cursor:pointer!important; } .menu-lewe a { background:#FAFAFA; padding:8px 8px; border-radius: 8px; display: inline-block; outline: none; color:#0C3658!important; font-weight:600!important; font-size:16px!important; line-height: 150% !important;} .menu-lewe{margin-bottom: 8px!important;} .kolumna-tekst{    flex-basis:35%!important;} .compact-nag{display:none!important; } .naglowek-duzy {margin-bottom:24px!important; margin-top: 48px!important; font-size:25px!important; font-style:normal; font-weight:600!important; letter-spacing:-0.25px!important; line-height:1.2!important;} .naglowek-maly {margin-bottom:20px!important; font-size:19px!important; font-style:normal; font-weight:700!important; letter-spacing:-0.02em!important; line-height:1.2!important;} .naglowek-start {margin-bottom:40px!important; margin-top: 0px!important; font-size:25px!important; font-style:normal; font-weight:600!important; letter-spacing:-0.02em!important; line-height:1.2!important;}  .tekst-para {font-size:17px!important;line-height:160%!important;margin-bottom:24px!important;} .tekst-para-maly {font-size:14px!important;line-height:160%!important;margin-bottom:24px!important;} .prawy-tytul{font-size:16px!important;} .prawy-tekst {font-size:14px!important;} .prawy-link a{font-size:16px!important;} .spis { display:block!important; } .spis2 { display:block!important; } .pasek-lewy { margin-left:7%!important; } .pasek-prawy {  margin-right:7%!important; } } @media(min-width: 1440px) and (max-width:1727px) { .tytulek{font-size:34px!important;max-width: 1200px!important;} .sekcja-tekst { margin-left: 40px!important; margin-right: 40px!important;} .artykul{margin-bottom:120px!important; margin-top:120px!important;} .menu-lewe a:hover { background:#E9F4FE!important; font-weight:600!important; font-size:16px!important; cursor:pointer!important; } .menu-lewe a { background:#FAFAFA; padding:8px 8px; border-radius: 8px; display: inline-block; outline: none; color:#0C3658!important; font-weight:600!important; font-size:16px!important; line-height: 150% !important;} .menu-lewe{margin-bottom: 8px!important;} .kolumna-tekst{flex-basis:35%!important;} .compact-nag{display:none!important; } .naglowek-duzy {margin-bottom:24px!important; margin-top: 48px!important; font-size:25px!important; font-style:normal; font-weight:600!important; letter-spacing:-0.25px!important; line-height:1.2!important;} .naglowek-maly {margin-bottom:20px!important; font-size:19px!important; font-style:normal; font-weight:700!important; letter-spacing:-0.02em!important; line-height:1.2!important;} .naglowek-start {margin-bottom:40px!important; margin-top: 0px!important; font-size:25px!important; font-style:normal; font-weight:600!important; letter-spacing:-0.02em!important; line-height:1.2!important;} .tekst-para {font-size:17px!important;line-height:160%!important;margin-bottom:24px!important;} .tekst-para-maly {font-size:14px!important;line-height:160%!important;margin-bottom:24px!important;} .prawy-tytul{font-size:16px!important;} .prawy-tekst {font-size:14px!important;} .prawy-link a{font-size:16px!important;} .spis { display:block!important; } .spis2 { display:block!important; } .pasek-lewy {  margin-left:7%!important; } .pasek-prawy {  margin-right:7%!important; } } @media (min-width: 1024px) and (max-width:1439px) { .tytulek{font-size:34px!important;max-width: 1200px!important;} .sekcja-tekst { margin-left: 40px!important; margin-right: 40px!important;} .artykul{margin-bottom:120px!important; margin-top:120px!important;} .menu-lewe a:hover { background:#E9F4FE!important; font-weight:600!important; font-size:16px!important; cursor:pointer!important; } .menu-lewe a { background:#FAFAFA; padding:8px 8px; border-radius: 8px; display: inline-block; outline: none; color:#0C3658!important; font-weight:600!important; font-size:16px!important; line-height: 150% !important;} .menu-lewe{margin-bottom: 8px!important;} .kolumna-tekst{flex-basis:35%!important;} .compact-nag{display:none!important; } .naglowek-duzy {margin-bottom:24px!important; margin-top: 32px!important; font-size:25px!important; font-style:normal; font-weight:600!important; letter-spacing:-0.25px!important; line-height:1.2!important;} .naglowek-maly {margin-bottom:20px!important; font-size:19px!important; font-style:normal; font-weight:700!important; letter-spacing:-0.02em!important; line-height:1.2!important;} .naglowek-start {margin-bottom:40px!important; margin-top: 0px!important; font-size:25px!important; font-style:normal; font-weight:600!important; letter-spacing:-0.02em!important; line-height:1.2!important;} .tekst-para {font-size:17px!important;line-height:160%!important;margin-bottom:24px!important;} .tekst-para-maly {font-size:14px!important;line-height:160%!important;margin-bottom:24px!important;} .prawy-tytul{font-size:16px!important;} .prawy-tekst {font-size:14px!important;} .prawy-link a{font-size:16px!important;} .spis { display:block!important; } .spis2{ display:block!important; } .pasek-lewy {  margin-left:7%!important; } .pasek-prawy {  margin-right:7%!important; } } @media (min-width: 782px) and (max-width:1023px) { .tytulek{font-size:25px!important;max-width: 1200px!important;} .sekcja-tekst { margin-left: 40px!important; margin-right: 40px!important;}  .artykul{margin-bottom:80px!important; margin-top:30px!important;} .menu-lewe a:hover { background:#E9F4FE!important; font-weight:600!important; font-size:14px!important; cursor:pointer!important; } .menu-lewe a { background:#FAFAFA; padding:10px 4px; border-radius: 8px; display: inline-block; outline: none; color:#0C3658!important; font-weight:600!important; font-size:14px!important; line-height: 150% !important;}  .menu-lewe{margin-bottom: 8px!important;} .kolumna-tekst{flex-basis:60%!important;} .compact-nag{display:block!important; } .naglowek-duzy {margin-bottom:24px!important; margin-top: 32px!important; font-size:19px!important; font-style:normal; font-weight:600!important; letter-spacing:-0.19px!important; line-height:1.2!important;} .naglowek-maly {margin-bottom:20px!important; font-size:16px!important; font-style:normal; font-weight:700!important; letter-spacing:-0.02em!important; line-height:1.2!important;} .naglowek-start {margin-bottom:40px!important; margin-top: 32px!important; font-size:25px!important; font-style:normal; font-weight:600!important; letter-spacing:-0.02em!important; line-height:1.2!important;} .tekst-para {font-size:14px!important;line-height:160%!important;margin-bottom:24px!important;} .tekst-para-maly {font-size:12px!important;line-height:160%!important;margin-bottom:24px!important;} .prawy-tytul{font-size:16px!important;} .prawy-tekst {font-size:13px!important;} .prawy-link a{font-size:16px!important;} .spis { display:block!important; } .spis2 { display:none!important; } .pasek-lewy { margin-left:32px!important; } .pasek-prawy {margin-right:32px!important; } } @media (max-width:781px) {  .tytulek{font-size:25px!important;max-width: 1200px!important;} .sekcja-tekst { margin-left: 16px!important; margin-right: 16px!important;}  .artykul{margin-bottom:80px!important; margin-top:30px!important;} .menu-lewe a:hover { background:#E9F4FE!important; font-weight:600!important; font-size:14px!important; cursor:pointer!important; } .menu-lewe a { background:#FAFAFA; padding:10px 4px; border-radius: 8px; display: inline-block; outline: none; color:#0C3658!important; font-weight:600!important; font-size:14px!important; line-height: 150% !important;} .menu-lewe{margin-bottom: 8px!important;} .kolumna-tekst{flex-basis:100%!important;} .compact-nag{display:block!important; } .naglowek-duzy {margin-bottom:24px!important; margin-top: 48px!important; font-size:19px!important; font-style:normal; font-weight:600!important; letter-spacing:-0.19px!important; line-height:1.2!important;} .naglowek-maly {margin-bottom:20px!important; font-size:16px!important; font-style:normal; font-weight:700!important; letter-spacing:-0.02em!important; line-height:1.2!important;} .naglowek-start {margin-bottom:40px!important; margin-top: 32px!important; font-size:25px!important; font-style:normal; font-weight:600!important; letter-spacing:-0.02em!important; line-height:1.2!important;} .tekst-para {font-size:14px!important;line-height:160%!important;margin-bottom:24px!important;} .tekst-para-maly {font-size:12px!important;line-height:160%!important;margin-bottom:24px!important;} .prawy-tytul{font-size:16px!important;} .prawy-tekst {font-size:13px!important;} .prawy-link a{font-size:16px!important;} .spis { display:none!important; } .spis2 { display:none!important; } .pasek-lewy { margin-left:16px!important; } .pasek-prawy {margin-right:16px!important; } } .prawy-link a:hover { color:#145A92!important} .banner { margin-top:80px; margin-bottom:80px; } .jazda-nowsza { position:sticky!important; top: 120px; overflow: auto; max-height: 85vh; }  .fobrazek { margin-bottom: -40px!important; } .sekcja5-przycisk a:hover { background: linear-gradient(0deg, rgba(0, 0, 0, 0.15), rgba(0, 0, 0, 0.15)), #ED4B9E!important; }  .sekcja5-przycisk a:focus { background: linear-gradient(0deg, rgba(0, 0, 0, 0.15), rgba(0, 0, 0, 0.15)), #ED4B9E!important; } .vlp-layout-blogs .vlp-block-0 {font-weight: 600!important; } .prawy-tytul-pulpit {font-size:19px!important;} .ct-container-narrow {max-width: 1200px!important;}  :nth-last-child(1 of .tekst-para) {margin-bottom: 0px!important;} <\/style><script> function lewemenu(zm) { var elements = document.getElementsByClassName(\"menu-lewe\"); var i,link1,link2; for (i = 0; i < elements.length; i++) {    link1 = elements[i].getElementsByTagName(\"a\");     link1[0].style.fontWeight = \"600\";     link1[0].style.backgroundColor= \"#FAFAFA\"; } link2 = elements[zm].getElementsByTagName(\"a\"); link2[0].style.fontWeight = \"600\"; link2[0].style.backgroundColor= \"#E9F4FE\"; } <\/script><div class=\"wp-block-getwid-section alignfull alignfull getwid-margin-top-none getwid-margin-bottom-none getwid-section-content-full-width\"><div class=\"wp-block-getwid-section__wrapper getwid-padding-top-none getwid-padding-bottom-none getwid-padding-left-none getwid-padding-right-none getwid-margin-left-none getwid-margin-right-none\" style=\"min-height:100vh\"><div class=\"wp-block-getwid-section__inner-wrapper\"><div class=\"wp-block-getwid-section__background-holder\"><div class=\"wp-block-getwid-section__background has-background\" style=\"background-color:#fafafa\"><\/div><div class=\"wp-block-getwid-section__foreground\"><\/div><\/div><div class=\"wp-block-getwid-section__content\"><div class=\"wp-block-getwid-section__inner-content\"><div class=\"wp-block-columns alignfull artykul is-layout-flex wp-container-core-columns-is-layout-f96e3eba wp-block-columns-is-layout-flex\" style=\"margin-top:0px;margin-bottom:0px\"><div class=\"wp-block-column pasek-lewy spis jazda-nowsza is-layout-flow wp-block-column-is-layout-flow\"><div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-995f960e wp-block-columns-is-layout-flex\"><div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><p class=\"menu-lewe wp-elements-67c751d6ba738a0038a2c29bd8b49e44 wp-block-paragraph\" onclick=\"lewemenu(0)\"><a href=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section1\" data-type=\"URL\" data-id=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section1\"  style=\"font-size:clamp(14px, 0.875rem + ((1vw - 3.2px) * 0.391), 19px);font-style:normal;font-weight:600;line-height:1.2;color:#0c3658\">Why change?<\/a><\/p><p class=\"menu-lewe wp-elements-ed193d5663df124de37275362cbe3aee wp-block-paragraph\" onclick=\"lewemenu(1)\"><a href=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section2\" data-type=\"URL\" data-id=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section2\"  style=\"font-size:clamp(14px, 0.875rem + ((1vw - 3.2px) * 0.391), 19px);font-style:normal;font-weight:600;line-height:1.2;color:#0c3658\">Background \/ Definition<\/a><\/p><p class=\"menu-lewe wp-elements-e0f2994657cb1de988b627ec45cdc8d9 wp-block-paragraph\" onclick=\"lewemenu(2)\"><a href=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section3\" data-type=\"URL\" data-id=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section3\"  style=\"font-size:clamp(14px, 0.875rem + ((1vw - 3.2px) * 0.391), 19px);font-style:normal;font-weight:600;line-height:1.2;color:#0c3658\">Case-Style Mini-Examples<\/a><\/p><p class=\"menu-lewe wp-elements-e6afdeaab58ef260bc48ba63043de281 wp-block-paragraph\" onclick=\"lewemenu(3)\"><a href=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section4\" data-type=\"URL\" data-id=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section4\"  style=\"font-size:clamp(14px, 0.875rem + ((1vw - 3.2px) * 0.391), 19px);font-style:normal;font-weight:600;line-height:1.2;color:#0c3658\">What will change?<\/a><\/p><p class=\"menu-lewe wp-elements-132b84e424a4bdd359d80517939afd81 wp-block-paragraph\" onclick=\"lewemenu(4)\"><a href=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section5\" data-type=\"URL\" data-id=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section5\"  style=\"font-size:clamp(14px, 0.875rem + ((1vw - 3.2px) * 0.391), 19px);font-style:normal;font-weight:600;line-height:1.2;color:#0c3658\">What will not change?<\/a><\/p><p class=\"menu-lewe wp-elements-5dae256f48e83391546f0bfd9800e1b9 wp-block-paragraph\" onclick=\"lewemenu(5)\"><a href=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section6\" data-type=\"URL\" data-id=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section6\"  style=\"font-size:clamp(14px, 0.875rem + ((1vw - 3.2px) * 0.391), 19px);font-style:normal;font-weight:600;line-height:1.2;color:#0c3658\">Key management questions (Q\/A)<\/a><\/p><p class=\"menu-lewe wp-elements-3b5ec38492e0f446de2bfd9b564571d3 wp-block-paragraph\" onclick=\"lewemenu(6)\"><a href=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section7\" data-type=\"URL\" data-id=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section7\"  style=\"font-size:clamp(14px, 0.875rem + ((1vw - 3.2px) * 0.391), 19px);font-style:normal;font-weight:600;line-height:1.2;color:#0c3658\">Atomic Facts<\/a><\/p><p class=\"menu-lewe wp-elements-198eec11d83cb53c186d784e6ac920a9 wp-block-paragraph\" onclick=\"lewemenu(7)\"><a href=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section8\" data-type=\"URL\" data-id=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section8\"  style=\"font-size:clamp(14px, 0.875rem + ((1vw - 3.2px) * 0.391), 19px);font-style:normal;font-weight:600;line-height:1.2;color:#0c3658\">Mini-FAQ<\/a><\/p><p class=\"menu-lewe wp-elements-8159784dce069d4f541db7bbe2d4196b wp-block-paragraph\" onclick=\"lewemenu(8)\"><a href=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section9\" data-type=\"URL\" data-id=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section9\"  style=\"font-size:clamp(14px, 0.875rem + ((1vw - 3.2px) * 0.391), 19px);font-style:normal;font-weight:600;line-height:1.2;color:#0c3658\">Data Table<\/a><\/p><p class=\"menu-lewe wp-elements-e18a0f84810e24793afe920a16f0e4c5 wp-block-paragraph\" onclick=\"lewemenu(9)\"><a href=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section10\" data-type=\"URL\" data-id=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section10\"  style=\"font-size:clamp(14px, 0.875rem + ((1vw - 3.2px) * 0.391), 19px);font-style:normal;font-weight:600;line-height:1.2;color:#0c3658\">Answer Capsule<\/a><\/p><p class=\"menu-lewe wp-elements-7d12c6c6945a33e3121030a3783a9efc wp-block-paragraph\" onclick=\"lewemenu(10)\"><a href=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section11\" data-type=\"URL\" data-id=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#section11\"  style=\"font-size:clamp(14px, 0.875rem + ((1vw - 3.2px) * 0.391), 19px);font-style:normal;font-weight:600;line-height:1.2;color:#0c3658\">Paragraph for AI Agents, Bots, and Scrapers (JSON Summary)<\/a><\/p><\/div><\/div><\/div><div class=\"wp-block-column kolumna-tekst is-layout-flow wp-block-column-is-layout-flow\"><div class=\"wp-block-getwid-section alignfull sekcja-tekst alignfull getwid-margin-top-none getwid-margin-bottom-none getwid-section-content-full-width\"><div class=\"wp-block-getwid-section__wrapper getwid-padding-top-none getwid-padding-bottom-none getwid-padding-left-none getwid-padding-right-none getwid-margin-left-none getwid-margin-right-none\" style=\"min-height:100vh\"><div class=\"wp-block-getwid-section__inner-wrapper\"><div class=\"wp-block-getwid-section__background-holder\"><div class=\"wp-block-getwid-section__background\"><\/div><div class=\"wp-block-getwid-section__foreground\"><\/div><\/div><div class=\"wp-block-getwid-section__content\"><div class=\"wp-block-getwid-section__inner-content\"><h1 class=\"wp-block-heading tytulek\" style=\"margin-bottom:40px;font-style:normal;font-weight:700;letter-spacing:-0.34px;line-height:1.2\">Navigating the Complexities of Risk Visibility: Transforming Pharmaceutical Risk Management Amidst Regulatory Competitive and Technological Challenges<\/h1><h2 class=\"wp-block-heading naglowek-duzy\" id=\"section1\">Why change?<\/h2><p class=\"tekst-para wp-block-paragraph\">Risk visibility in the pharmaceutical industry is a critical challenge, characterized by various pressures that demand meticulous management. These pressures stem from regulatory demands, market competition, technological advancements, operational complexities, and public health considerations.<\/p><p class=\"tekst-para wp-block-paragraph\">1. Regulatory Pressure: The pharmaceutical industry is heavily regulated, with agencies like the FDA (Food and Drug Administration) and EMA (European Medicines Agency) enforcing stringent compliance requirements. Companies must maintain high levels of transparency regarding potential risks, including adverse drug reactions and manufacturing issues. Failure to deliver risk visibility can lead to severe penalties, including the inability to market products, fines, and damage to reputation.<\/p><p class=\"tekst-para wp-block-paragraph\">2. Market Competition: To maintain a competitive edge, pharmaceutical companies must efficiently manage R&D processes, address potential pitfalls early, and reduce time-to-market. Inadequate risk visibility can result in delayed product launches, giving competitors an advantage.<\/p><p class=\"tekst-para wp-block-paragraph\">3. Technological Advancements: The rapid pace of technological advancement in drug development and manufacturing necessitates continuous monitoring and assessment of risks. Companies must integrate new technologies effectively while mitigating associated risks.<\/p><p class=\"tekst-para wp-block-paragraph\">4. Operational Complexities: Pharmaceutical operations come with complex supply chains, global operations, and collaboration between diverse teams. Poor risk visibility can disrupt supply chains, lead to inefficiencies, and ultimately affect the bottom line.<\/p><p class=\"tekst-para wp-block-paragraph\">5. Public Health Considerations: The stakes in pharmaceuticals are uniquely high, as risks can directly impact public health. Companies must ensure visibility to preemptively identify and address any potential threats to consumer safety.<\/p><p class=\"tekst-para wp-block-paragraph\"> Quantifying the Risk of Inaction:<\/p><p class=\"tekst-para wp-block-paragraph\">- Regulatory Non-compliance: Failure to comply due to lack of risk visibility can result in removing products from the market, costing millions or even billions in lost revenue, alongside fines which can run into the millions.<\/p><p class=\"tekst-para wp-block-paragraph\">- Product Recalls: Inadequate risk management might lead to recalls, which cost an average of $8 million per incident, not including lost future sales and damage to brand reputation.<\/p><p class=\"tekst-para wp-block-paragraph\">- R&D Delays: Ineffective risk management in research and development might delay product launches, potentially losing millions in daily sales, with some drugs generating over $1 billion annually.<\/p><p class=\"tekst-para wp-block-paragraph\">- Litigation Costs: Legal expenses from litigation due to undisclosed or unmanaged risks can exceed $100 million in severe cases.<\/p><p class=\"tekst-para wp-block-paragraph\">- Loss of Market Share: The cost of market share loss due to delayed or restricted product launches can long-term, potentially impacting future revenue streams in the billions.<\/p><p class=\"tekst-para wp-block-paragraph\">While it\u2019s important to choose tools and solutions that facilitate enhanced risk visibility without being tied to a particular software, platforms like KanBo exemplify how collaborative tools can enable better risk management. KanBo can create a single source of truth, allowing teams to visualize and track risk across various projects or domains seamlessly, facilitating decision-making and improving response times across the organization.<\/p><p class=\"tekst-para wp-block-paragraph\">Ultimately, ensuring robust risk visibility is not just a compliance requirement in the pharmaceutical industry; it's a strategic imperative to protect market position, ensure operational efficiency, and uphold public trust.<\/p><h3 class=\"wp-block-heading naglowek-duzy\" id=\"section2\">Background \/ Definition<\/h3><p class=\"tekst-para wp-block-paragraph\">Risk Visibility for Combined Products in Pharmaceutical<\/p><p class=\"tekst-para wp-block-paragraph\">In the pharmaceutical industry, particularly when dealing with combined products (such as drugs with device components), risk visibility is crucial for ensuring product safety, efficacy, and compliance with regulatory standards. Risk visibility refers to the clear identification, assessment, tracking, and communication of potential risks throughout the product lifecycle. It ensures that all stakeholders\u2014from development teams to regulatory bodies\u2014are aware of the risks and can make informed decisions to mitigate them.<\/p><p class=\"tekst-para wp-block-paragraph\">Key Terms in Risk Visibility<\/p><p class=\"tekst-para wp-block-paragraph\">1. Card Blockers: These are obstacles that prevent tasks from advancing. In risk management, identifying and addressing card blockers\u2014such as regulatory hurdles or critical design flaws\u2014is vital for minimizing delays and ensuring a smooth development process. KanBo identifies card blockers as local (specific to one task), global (impacting multiple tasks), or on-demand (emerging as needed).<\/p><p class=\"tekst-para wp-block-paragraph\">2. Date Conflict: In project management, particularly in pharmaceuticals, date conflicts can cause significant issues. This occurs when related tasks have overlapping or inconsistent deadlines, potentially leading to scheduling conflicts and prioritization problems. Resolving date conflicts ensures that risk assessments and regulatory submissions occur in a timely manner.<\/p><p class=\"tekst-para wp-block-paragraph\">3. Card Relation: Defining relationships between different tasks (or 'cards' in KanBo) helps in breaking down complex processes into manageable steps. Understanding these relationships is crucial for risk management, as it allows teams to identify how delays or changes in one task (card) might impact others.<\/p><p class=\"tekst-para wp-block-paragraph\">4. Notification: Notifications serve as crucial alerts to stakeholders about important changes or updates regarding risk-related tasks. Whether it's receiving alerts about regulatory updates, changes in risk assessment status, or critical feedback from a health authority, timely notifications keep everyone aligned and responsive.<\/p><p class=\"tekst-para wp-block-paragraph\">KanBo\u2019s Approach to Reframing Risk Visibility<\/p><p class=\"tekst-para wp-block-paragraph\">KanBo provides a robust platform to enhance risk visibility through the incorporation of visible blockers, mapped dependencies, and notifications.<\/p><p class=\"tekst-para wp-block-paragraph\">1. Visible Blockers: KanBo allows users to categorize and visualize blockers directly on their boards. This visibility makes it easier for risk managers to identify, prioritize, and address issues promptly. By making blockers explicit, KanBo helps teams preemptively manage risks before they become critical issues.<\/p><p class=\"tekst-para wp-block-paragraph\">2. Mapped Dependencies: Through its card relation feature, KanBo helps users map out task dependencies, effectively splitting larger processes into smaller, structured elements. This mapping enhances understanding of task interrelations and their potential risk implications, supporting better planning and risk mitigation strategies.<\/p><p class=\"tekst-para wp-block-paragraph\">3. Notifications: KanBo enhances communication and responsiveness through its notification system. Users receive real-time updates on any changes related to their tasks, such as when a task encounters a blocker or when the status of a risk-related task is updated. This feature ensures that all stakeholders remain informed and can quickly react to emerging risks.<\/p><p class=\"tekst-para wp-block-paragraph\">By integrating these features, KanBo provides a comprehensive solution for maintaining high levels of risk visibility in the pharmaceutical sector. This approach not only aids in effective risk management for combined products but also streamlines the process of ensuring compliance and safety, ultimately contributing to the successful launch and lifecycle management of pharmaceutical products.<\/p><h3 class=\"wp-block-heading naglowek-duzy\" id=\"section3\">Case-Style Mini-Examples<\/h3><p class=\"tekst-para wp-block-paragraph\">Practical Example: Managing Risk Visibility in Combined Products with Traditional Methods vs. KanBo<\/p><p class=\"tekst-para wp-block-paragraph\">Scenario:<\/p><p class=\"tekst-para wp-block-paragraph\">Dr. Sarah Thompson, a Risk Management Expert at a pharmaceutical company, oversees risk management for combined products. She faces challenges in monitoring potential risks throughout the lifecycle of a new drug-device combination product. The traditional methods her company uses often result in delays and inefficiencies, impacting the project's timeline and increasing compliance risks.<\/p><p class=\"tekst-para wp-block-paragraph\">Traditional Method Challenges:<\/p><p class=\"tekst-para wp-block-paragraph\">1. Card Blocker Oversight:<\/p><p class=\"tekst-para wp-block-paragraph\">   - Using outdated spreadsheets and email chains, Sarah struggles to track and communicate critical blockers like regulatory approvals and design flaws. Often, these blockers are discovered late, causing costly delays in the project timeline.<\/p><p class=\"tekst-para wp-block-paragraph\">2. Date Conflict Confusion:<\/p><p class=\"tekst-para wp-block-paragraph\">   - Task timelines are managed in separate documents, leading to frequent date conflicts. Overlapping due dates for critical tasks result in resources being double-booked and prioritization issues, further delaying progress.<\/p><p class=\"tekst-para wp-block-paragraph\">3. Disjointed Card Relations:<\/p><p class=\"tekst-para wp-block-paragraph\">   - There is limited visibility into how tasks are interconnected. The lack of structured task dependency mapping increases the risk of oversight, as certain tasks get delayed, impacting downstream activities.<\/p><p class=\"tekst-para wp-block-paragraph\">4. Inefficient Notifications:<\/p><p class=\"tekst-para wp-block-paragraph\">   - Key updates and alerts from regulatory bodies are communicated through disjointed email threads, leading to missed deadlines and lack of awareness among stakeholders.<\/p><p class=\"tekst-para wp-block-paragraph\">Using KanBo to Enhance Risk Visibility:<\/p><p class=\"tekst-para wp-block-paragraph\">Sarah\u2019s company transitions to KanBo to address these inefficiencies. Here\u2019s how KanBo facilitates improved risk management:<\/p><p class=\"tekst-para wp-block-paragraph\">1. Visible Blockers:<\/p><p class=\"tekst-para wp-block-paragraph\">   - KanBo's card blocker feature allows Sarah to visualize blockers directly on her board. She categorizes them as local, global, and on-demand, enabling the team to prioritize and address issues before they become critical.<\/p><p class=\"tekst-para wp-block-paragraph\">2. Resolving Date Conflicts:<\/p><p class=\"tekst-para wp-block-paragraph\">   - The date dependency feature in KanBo helps Sarah identify and resolve date conflicts early. She uses the Gantt Chart view to synchronize timelines across tasks, ensuring no overlap and streamlining resource allocation.<\/p><p class=\"tekst-para wp-block-paragraph\">3. Structured Card Relations:<\/p><p class=\"tekst-para wp-block-paragraph\">   - With KanBo\u2019s card relation feature, Sarah maps out parent-child and previous-next connections between tasks. This transparency clarifies the order of tasks, helping the team to address dependencies and prevent bottlenecks effectively.<\/p><p class=\"tekst-para wp-block-paragraph\">4. Efficient Notifications:<\/p><p class=\"tekst-para wp-block-paragraph\">   - KanBo\u2019s notification system keeps Sarah and her team updated in real-time. Important changes in task status, comments from regulators, and updates on compliance are instantly communicated, ensuring prompt responses to emerging risks.<\/p><p class=\"tekst-para wp-block-paragraph\">Outcome:<\/p><p class=\"tekst-para wp-block-paragraph\">By transitioning to KanBo, Sarah\u2019s team significantly improves risk visibility and management efficiency. The proactive identification and resolution of blockers, along with streamlined communication and task dependencies, contribute to a more harmonious workflow. This leads to faster project delivery, reduced risk of compliance issues, and maintains the company's competitive edge in the market.<\/p><p class=\"tekst-para wp-block-paragraph\">Executive Summary:<\/p><p class=\"tekst-para wp-block-paragraph\">In the pharmaceutical sector, risk visibility is vital for the success and compliance of combined products. This example illustrates the traditional challenges related to card blockers, date conflicts, task dependencies, and notifications. With KanBo, these challenges are effectively mitigated, resulting in enhanced risk management and successful product launches. KanBo\u2019s robust features enable teams to better visualize and manage risks, directly contributing to organizational success by reducing delays, improving compliance, and enhancing operational efficiency.<\/p><h3 class=\"wp-block-heading naglowek-duzy\" id=\"section4\">What will change?<\/h3><p class=\"tekst-para wp-block-paragraph\">In the realm of pharmaceutical risk management, particularly for combined products, traditional tools and outdated methods often fell short in providing the necessary visibility and control over risks throughout the product lifecycle. These old-school approaches typically involved siloed spreadsheets, manual tracking, and inconsistent communication paths, leading to inefficiencies and increased risk of non-compliance.<\/p><p class=\"tekst-para wp-block-paragraph\">Transition from Old-School Tools to KanBo<\/p><p class=\"tekst-para wp-block-paragraph\">1. Spreadsheets to Card-Based Systems:<\/p><p class=\"tekst-para wp-block-paragraph\">   - Old Method: Static spreadsheets lacked real-time updates and collaborative capabilities, often leading to outdated risk assessments and overlooked critical changes.<\/p><p class=\"tekst-para wp-block-paragraph\">   - KanBo Approach: Utilizes cards within spaces for live tracking and updates on risk management tasks, allowing for dynamic data handling and collaborative input from multiple stakeholders.<\/p><p class=\"tekst-para wp-block-paragraph\">2. Manual Tracking to Automated Notification Systems:<\/p><p class=\"tekst-para wp-block-paragraph\">   - Old Method: Relying on emails or manual updates meant stakeholders often missed critical information or received it too late to act effectively.<\/p><p class=\"tekst-para wp-block-paragraph\">   - KanBo Approach: Automated notifications ensure stakeholders receive instant alerts on risk-related changes or updates, facilitating timely decision-making and proactive risk management.<\/p><p class=\"tekst-para wp-block-paragraph\">3. Siloed Data to Integrated Document Management:<\/p><p class=\"tekst-para wp-block-paragraph\">   - Old Method: Storing documents in disparate locations led to version control issues and hindered the ability to access up-to-date information when needed.<\/p><p class=\"tekst-para wp-block-paragraph\">   - KanBo Approach: Integration with document libraries like SharePoint consolidates document access, ensuring all team members work with the most current and relevant data, crucial for risk assessments and regulatory submissions.<\/p><p class=\"tekst-para wp-block-paragraph\">4. Isolated Planning to Visual Task Management:<\/p><p class=\"tekst-para wp-block-paragraph\">   - Old Method: Risk plans often existed in isolation, making it difficult to see the bigger picture or understand task dependencies within the product development lifecycle.<\/p><p class=\"tekst-para wp-block-paragraph\">   - KanBo Approach: Visual tools such as Gantt and Mind Map views offer a comprehensive overview of task dependencies and critical paths, enhancing risk visibility and strategic planning.<\/p><p class=\"tekst-para wp-block-paragraph\">By replacing outdated methods with KanBo\u2019s modern, integrated platform, pharmaceutical companies can significantly enhance risk visibility for combined products. This ensures a robust risk management process, streamlines compliance, and supports the successful development and launch of safe, effective pharmaceutical products.<\/p><h3 class=\"wp-block-heading naglowek-duzy\" id=\"section5\">What will not change?<\/h3><p class=\"tekst-para wp-block-paragraph\">In the context of Risk Visibility for combined pharmaceutical products, certain elements remain steadfast despite technological advancements. Leadership judgment, strategy ownership, and accountability continue to be inherently human roles; technology serves to enhance these aspects, but cannot replace them. These constants underscore the importance of maintaining a human-first approach, where empathy, ethical considerations, and critical decision-making drive risk management practices, with technology acting as a powerful tool to support and amplify these efforts.<\/p><h3 class=\"wp-block-heading naglowek-duzy\" id=\"section6\">Key management questions (Q\/A)<\/h3><p class=\"tekst-para wp-block-paragraph\">1. Who did what and when?  <\/p><p class=\"tekst-para wp-block-paragraph\">   - Tasks and responsibilities should be clearly documented using a collaborative platform like KanBo, where each action is logged with a timestamp, showing who completed what task at what time, ensuring accountability and traceability.<\/p><p class=\"tekst-para wp-block-paragraph\">2. What threatens the critical path?  <\/p><p class=\"tekst-para wp-block-paragraph\">   - Potential threats include unresolved regulatory hurdles, critical design flaws, insufficient resource allocation, or unforeseen technical difficulties that can cause delays, impacting the overall project timeline.<\/p><p class=\"tekst-para wp-block-paragraph\">3. Where are bottlenecks?  <\/p><p class=\"tekst-para wp-block-paragraph\">   - Bottlenecks may occur in regulatory compliance processes, supply chain management, or due to lack of data integration among development teams, hindering seamless progression of tasks.<\/p><p class=\"tekst-para wp-block-paragraph\">4. Which tasks are overdue and why?  <\/p><p class=\"tekst-para wp-block-paragraph\">   - Tasks could be overdue due to unforeseen complexities, inadequate resource allocation, high workload on team members, or unresolved risk factors identified as card blockers requiring additional resolution time.<\/p><h3 class=\"wp-block-heading naglowek-duzy\" id=\"section7\">Atomic Facts<\/h3><p class=\"tekst-para wp-block-paragraph\">- Regulatory Compliance: A lack of risk visibility can lead to severe regulatory consequences. Non-compliance may result in fines exceeding millions of dollars and the inability to market products, drastically affecting revenue streams and company reputation.<\/p><p class=\"tekst-para wp-block-paragraph\">- Product Recalls: Inadequate visibility into potential risks can lead to product recalls, which on average cost pharmaceutical companies around $8 million per incident, excluding additional costs from long-term brand damage and lost market share.<\/p><p class=\"tekst-para wp-block-paragraph\">- R&D Inefficiencies: Delays in R&D due to unmanaged risks can postpone product launches, potentially costing companies millions in daily revenue, especially when dealing with blockbuster drugs exceeding $1 billion in annual sales.<\/p><p class=\"tekst-para wp-block-paragraph\">- Litigation Risks: Without effective risk visibility, undisclosed or unmanaged risks can lead to litigation with associated costs that can reach over $100 million, highlighting the financial impact of inadequate risk management.<\/p><p class=\"tekst-para wp-block-paragraph\">- Technological Integration: For every dollar invested in new technology, it is crucial to have robust risk visibility mechanisms to avoid disruptions and inefficiencies, ensuring successful integration and operation within existing pharmaceutical processes.<\/p><p class=\"tekst-para wp-block-paragraph\">- Supply Chain Disruptions: Poor risk visibility in the complex, global supply chains of pharmaceuticals can result in significant operational inefficiencies, jeopardizing product availability and company reliability.<\/p><p class=\"tekst-para wp-block-paragraph\">- Public Health Impact: Effective risk visibility aids in promptly mitigating threats to consumer safety, maintaining public trust and safeguarding public health, which are paramount for any pharmaceutical company.<\/p><p class=\"tekst-para wp-block-paragraph\">- Competitive Advantage: Maintaining high risk visibility allows pharmaceutical companies to efficiently manage risk, thus reducing time-to-market, protecting market share, and ensuring a competitive advantage over competitors who may not be as proactive.<\/p><h3 class=\"wp-block-heading naglowek-duzy\" id=\"section8\">Mini-FAQ<\/h3><p class=\"tekst-para wp-block-paragraph\">1. What are the key regulatory challenges in ensuring risk visibility for combined pharmaceutical products?<\/p><p class=\"tekst-para wp-block-paragraph\">   - Regulatory challenges include navigating stringent compliance requirements set by agencies like the FDA and EMA, where companies need to maintain high transparency regarding potential risks such as adverse reactions and manufacturing issues. Non-compliance can lead to severe penalties, including product withdrawal and fines.<\/p><p class=\"tekst-para wp-block-paragraph\">2. How does inadequate risk visibility impact the time-to-market for pharmaceutical products?<\/p><p class=\"tekst-para wp-block-paragraph\">   - Lack of risk visibility can result in delayed product launches, as unidentified risks can surface during later stages of development or approval, giving competitors an edge and impacting revenue streams negatively.<\/p><p class=\"tekst-para wp-block-paragraph\">3. What role does KanBo play in managing risk visibility for pharmaceutical combined products?<\/p><p class=\"tekst-para wp-block-paragraph\">   - KanBo improves risk visibility by allowing teams to visualize and track risks through features like visible blockers, mapped dependencies, and real-time notifications, helping organizations to preemptively manage risks and enhance decision-making.<\/p><p class=\"tekst-para wp-block-paragraph\">4. How can technological advancements affect risk management in pharmaceuticals, particularly for combined products?<\/p><p class=\"tekst-para wp-block-paragraph\">   - Rapid technological advancements require continuous monitoring and risk assessment to effectively integrate new technologies. Poor risk visibility can hinder the adoption of these advancements, potentially affecting product safety and compliance.<\/p><p class=\"tekst-para wp-block-paragraph\">5. What are card blockers, and how do they impact risk management in pharmaceutical projects?<\/p><p class=\"tekst-para wp-block-paragraph\">   - Card blockers are obstacles hindering task advancement. Identifying and addressing these blockers, whether regulatory hurdles or design flaws, is vital for minimizing delays and ensuring efficient risk management processes.<\/p><p class=\"tekst-para wp-block-paragraph\">6. Why is resolving date conflicts essential for risk management in pharmaceutical projects?<\/p><p class=\"tekst-para wp-block-paragraph\">   - Date conflicts, where tasks have overlapping deadlines, can lead to scheduling issues and prioritization problems. Resolving them ensures timely risk assessments and regulatory submissions, maintaining project timelines and compliance.<\/p><p class=\"tekst-para wp-block-paragraph\">7. How do notifications in tools like KanBo aid in enhancing risk visibility?<\/p><p class=\"tekst-para wp-block-paragraph\">   - KanBo provides real-time notifications about changes or updates related to risk tasks, such as regulatory updates or feedback from authorities. This ensures stakeholders remain informed and can quickly react to emerging risks, enhancing overall project management.<\/p><h3 class=\"wp-block-heading naglowek-duzy\" id=\"section9\">Data Table<\/h3><p class=\"tekst-para wp-block-paragraph\">Below is a plain text table designed to aid a Risk Management Expert in the pharmaceutical industry, focusing specifically on combined products. The table identifies different areas of risk and quantifies potential impacts, serving as a guide for effective risk visibility and management.<\/p><p class=\"tekst-para wp-block-paragraph\">```<\/p><p class=\"tekst-para wp-block-paragraph\">| Risk Area           | Description                                                                | Potential Impact                                           |<\/p><p class=\"tekst-para wp-block-paragraph\">|-------------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------|<\/p><p class=\"tekst-para wp-block-paragraph\">| Regulatory Pressure     | Compliance with FDA, EMA, and other regulations                               | Penalties, loss of market access, reputational damage         |<\/p><p class=\"tekst-para wp-block-paragraph\">| Market Competition      | Maintaining competitive edge in R&D and time-to-market                       | Delayed launches, loss of market share, reduced revenue       |<\/p><p class=\"tekst-para wp-block-paragraph\">| Technological Advancements | Risks associated with integrating new technologies                          | Implementation failures, increased costs, inefficiencies      |<\/p><p class=\"tekst-para wp-block-paragraph\">| Operational Complexities | Risks from complex supply chains, global operations, and team collaborations  | Disruptions, inefficiencies, profitability issues             |<\/p><p class=\"tekst-para wp-block-paragraph\">| Public Health Considerations | Potential threats to consumer safety due to inadequate risk visibility   | Product recalls, damage to reputation, public distrust        |<\/p><p class=\"tekst-para wp-block-paragraph\">| Outcome of Inaction | Potential Financial Impact                                                 |<\/p><p class=\"tekst-para wp-block-paragraph\">|-------------------------|--------------------------------------------------------------------------------|<\/p><p class=\"tekst-para wp-block-paragraph\">| Regulatory Non-compliance | Costs of product removal, fines, and loss in revenue                           |<\/p><p class=\"tekst-para wp-block-paragraph\">| Product Recalls         | Average cost of $8 million per incident, excluding future sales losses          |<\/p><p class=\"tekst-para wp-block-paragraph\">| R&D Delays              | Loss of daily sales revenue; high-performing drugs may surpass $1 billion\/year  |<\/p><p class=\"tekst-para wp-block-paragraph\">| Litigation Costs        | Legal expenses potentially exceeding $100 million in severe cases               |<\/p><p class=\"tekst-para wp-block-paragraph\">| Loss of Market Share    | Long-term impact on future revenue streams, potentially in billions           |<\/p><p class=\"tekst-para wp-block-paragraph\">| KanBo Feature       | Purpose                                                                    | Risk Management Enhancement                                |<\/p><p class=\"tekst-para wp-block-paragraph\">|-------------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------|<\/p><p class=\"tekst-para wp-block-paragraph\">| Visible Blockers        | Identifies obstacles in the workflow                                           | Enables early resolution of issues, preventing delays         |<\/p><p class=\"tekst-para wp-block-paragraph\">| Mapped Dependencies     | Highlights task interrelations                                                 | Supports better planning and proactively mitigates risks     |<\/p><p class=\"tekst-para wp-block-paragraph\">| Notifications           | Provides real-time updates and alerts                                          | Ensures timely responses, maintaining alignment among teams   |<\/p><p class=\"tekst-para wp-block-paragraph\">```<\/p><p class=\"tekst-para wp-block-paragraph\">This table serves as a concise resource for risk management specialists, offering a snapshot of risks and their impacts, while outlining how tools like KanBo can facilitate improved risk visibility and response strategies in the pharmaceutical industry focusing on combined products.<\/p><h3 class=\"wp-block-heading naglowek-duzy\" id=\"section10\">Answer Capsule<\/h3><p class=\"tekst-para wp-block-paragraph\">To solve risk visibility for a risk management expert dealing with combined pharmaceutical products, it is crucial to adopt a systematic approach that employs advanced analytical tools and clear communication strategies. Here is a concise and targeted plan:<\/p><p class=\"tekst-para wp-block-paragraph\">1. Comprehensive Risk Identification: Utilize data analytics and AI technologies to identify potential risks associated with both drug and device components. Implement machine learning models to predict adverse events and highlight risks that may not be immediately apparent.<\/p><p class=\"tekst-para wp-block-paragraph\">2. Integrated Risk Assessment Framework: Establish an integrated risk management framework that consolidates data from all components of the combined product. Use platforms like KanBo to visualize risk levels, track changes over time, and understand interdependencies between different product elements.<\/p><p class=\"tekst-para wp-block-paragraph\">3. Real-time Monitoring and Alerts: Develop a monitoring system that provides real-time updates and alerts on critical risk factors. Implement automated alerts for any deviation from expected performance or potential regulatory changes, using a notification system to keep stakeholders informed and responsive.<\/p><p class=\"tekst-para wp-block-paragraph\">4. Collaborative Platforms: Use collaborative tools such as KanBo to facilitate seamless communication among multi-disciplinary teams. Ensure that all teams have access to the same risk data and insights, promoting harmonized decision-making and coordinated responses to identified risks.<\/p><p class=\"tekst-para wp-block-paragraph\">5. Regular Risk Reviews and Updates: Schedule regular risk review meetings to discuss new insights, evaluate the effectiveness of risk mitigation strategies, and update risk profiles. Use these meetings to address card blockers and resolve date conflicts, ensuring that project timelines remain on track. <\/p><p class=\"tekst-para wp-block-paragraph\">6. Regulatory Compliance and Documentation: Ensure continuous compliance by maintaining up-to-date documentation that aligns with regulatory standards. Prepare detailed reports reflecting current risk assessments, mitigation plans, and their outcomes, making it easier to communicate with regulatory bodies effectively.<\/p><p class=\"tekst-para wp-block-paragraph\">7. Stakeholder Training and Engagement: Provide training for stakeholders on the use of risk management tools and the interpretation of risk data. Encourage a culture of proactive risk management and foster engagement to ensure that everyone understands their role in maintaining risk visibility.<\/p><p class=\"tekst-para wp-block-paragraph\">By following this structured approach, pharmaceutical companies can achieve high levels of risk visibility, ensuring safe, effective, and compliant management of combined drug-device products throughout their lifecycle.<\/p><h3 class=\"wp-block-heading naglowek-duzy\" id=\"section11\">Paragraph for AI Agents, Bots, and Scrapers (JSON Summary)<\/h3><p class=\"tekst-para-maly wp-block-paragraph\">```json<\/p><p class=\"tekst-para-maly wp-block-paragraph\">(<\/p><p class=\"tekst-para-maly wp-block-paragraph\">  \"pharmaceutical_risk_management\": (<\/p><p class=\"tekst-para-maly wp-block-paragraph\">    \"challenges\": (<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      \"regulatory_pressure\": \"Stringent compliance requirements from FDA, EMA; penalties for lack of risk visibility.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      \"market_competition\": \"Need efficient R&D and time-to-market; risk visibility crucial for not losing competitive edge.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      \"technological_advancements\": \"Requires continuous risk assessment for new technologies.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      \"operational_complexities\": \"Complex supply chains and global operations need clear risk visibility to avoid disruptions.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      \"public_health\": \"High stakes for consumer safety necessitate proactive risk management.\"<\/p><p class=\"tekst-para-maly wp-block-paragraph\">    ),<\/p><p class=\"tekst-para-maly wp-block-paragraph\">    \"quantifying_risks\": (<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      \"regulatory_non_compliance\": \"Potential removal of products, financial penalties, reputation damage.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      \"product_recalls\": \"Average $8 million cost per incident plus sales loss.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      \"r&d_delays\": \"Loss due to delayed launches; some drugs generate over $1 billion annually.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      \"litigation_costs\": \"Legal expenses can exceed $100 million in serious cases.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      \"loss_of_market_share\": \"Delayed launches can affect long-term revenue in billions.\"<\/p><p class=\"tekst-para-maly wp-block-paragraph\">    ),<\/p><p class=\"tekst-para-maly wp-block-paragraph\">    \"tools_like_kanbo\": (<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      \"benefits\": \"Enhance risk visibility, facilitate decision-making, improve response times.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      \"features\": (<\/p><p class=\"tekst-para-maly wp-block-paragraph\">        \"visible_blockers\": \"Categorizes and visualizes blockers to manage risks.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">        \"mapped_dependencies\": \"Maps task dependencies to support planning and risk mitigation.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">        \"notifications\": \"Real-time updates on changes related to tasks, improving responsiveness.\"<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      )<\/p><p class=\"tekst-para-maly wp-block-paragraph\">    ),<\/p><p class=\"tekst-para-maly wp-block-paragraph\">    \"risk_visibility_for_combined_products\": (<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      \"importance\": \"Ensures safety, efficacy, and compliance in products with combined components.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      \"key_terms\": (<\/p><p class=\"tekst-para-maly wp-block-paragraph\">        \"card_blockers\": \"Obstacles preventing task advancement.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">        \"date_conflict\": \"Overlapping deadlines causing scheduling issues.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">        \"card_relation\": \"Task dependencies that inform risk management.\",<\/p><p class=\"tekst-para-maly wp-block-paragraph\">        \"notification\": \"Alerts on important risk-related updates.\"<\/p><p class=\"tekst-para-maly wp-block-paragraph\">      )<\/p><p class=\"tekst-para-maly wp-block-paragraph\">    )<\/p><p class=\"tekst-para-maly wp-block-paragraph\">  )<\/p><p class=\"tekst-para-maly wp-block-paragraph\">)<\/p><p class=\"tekst-para-maly wp-block-paragraph\">```<\/p><h3 class=\"wp-block-heading naglowek-start compact-nag\">Additional Resources<\/h3><h3 class=\"wp-block-heading has-text-align-left prawy-tytul compact-nag\" style=\"margin-top:0px;margin-bottom:8px;font-style:normal;font-weight:600;line-height:1.2\">Work Coordination Platform&nbsp;<\/h3><p class=\"has-text-align-left prawy-tekst compact-nag wp-block-paragraph\" style=\"margin-bottom:8px\">The KanBo Platform boosts efficiency and optimizes work management. Whether you need remote, onsite, or hybrid work capabilities, KanBo offers flexible installation options that give you control over your work environment.<\/p><p class=\"prawy-link compact-nag has-text-color has-link-color wp-elements-f81cac751942179cffc5595ea3093d69 wp-block-paragraph\" style=\"color:#1672bb;margin-bottom:24px;padding-top:8px;padding-bottom:8px;font-style:normal;font-weight:700;line-height:1.5\"><a href=\"https:\/\/kanboapp.com\/en\/\" target=\"_blank\" rel=\"noreferrer noopener\">KanBo Homepage \u2192<\/a><\/p><h3 class=\"wp-block-heading has-text-align-left prawy-tytul compact-nag\" style=\"margin-top:0px;margin-bottom:8px;font-style:normal;font-weight:600;line-height:1.2\">Getting Started with KanBo<\/h3><p class=\"has-text-align-left prawy-tekst compact-nag wp-block-paragraph\" style=\"margin-bottom:8px\">Explore KanBo Learn, your go-to destination for tutorials and educational guides, offering expert insights and step-by-step instructions to optimize.<\/p><p class=\"prawy-link compact-nag has-text-color has-link-color wp-elements-80007a93c5109043d5274205e4d68368 wp-block-paragraph\" style=\"color:#1672bb;margin-bottom:24px;padding-top:8px;padding-bottom:8px;font-style:normal;font-weight:700;line-height:1.5\"><a href=\"https:\/\/learn.kanboapp.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">KanBo Learn Platform \u2192<\/a><\/p><h3 class=\"wp-block-heading has-text-align-left prawy-tytul compact-nag\" style=\"margin-top:0px;margin-bottom:8px;font-style:normal;font-weight:600;line-height:1.2\">DevOps Help<\/h3><p class=\"has-text-align-left prawy-tekst compact-nag wp-block-paragraph\" style=\"margin-bottom:8px\">Explore Kanbo's DevOps guide to discover essential strategies for optimizing collaboration, automating processes, and improving team efficiency.<\/p><p class=\"prawy-link compact-nag has-text-color has-link-color wp-elements-23fbce8bb46a861d3991ae1a29f1d971 wp-block-paragraph\" style=\"color:#1672bb;margin-bottom:0px;padding-top:8px;padding-bottom:8px;font-style:normal;font-weight:700;line-height:1.5\"><a href=\"https:\/\/help.kanboapp.com\/en\/devops\/\" target=\"_blank\" rel=\"noreferrer noopener\">KanBo Dev Portal \u2192<\/a><\/p><\/div><\/div><\/div><\/div><\/div><\/div><div class=\"wp-block-column pasek-prawy spis2 jazda-nowsza is-layout-flow wp-block-column-is-layout-flow\"><div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-995f960e wp-block-columns-is-layout-flex\"><div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"padding-right:16px;padding-left:16px\"><h3 class=\"wp-block-heading has-text-align-left prawy-tytul-pulpit\" style=\"margin-top:0px;margin-bottom:8px;font-style:normal;font-weight:600;line-height:1.2\">Work Coordination Platform&nbsp;<\/h3><p class=\"has-text-align-left prawy-tekst wp-block-paragraph\" style=\"margin-bottom:8px\">The KanBo Platform boosts efficiency and optimizes work management. Whether you need remote, onsite, or hybrid work capabilities, KanBo offers flexible installation options that give you control over your work environment.<\/p><p class=\"prawy-link has-text-color has-link-color wp-elements-40115c86dc2fe150fd9b1ed5dc10196e wp-block-paragraph\" style=\"color:#1672bb;margin-bottom:32px;padding-top:8px;padding-bottom:8px;font-style:normal;font-weight:700;line-height:1.5\"><a href=\"https:\/\/kanboapp.com\/en\/\" target=\"_blank\" rel=\"noreferrer noopener\">KanBo Homepage \u2192<\/a><\/p><h3 class=\"wp-block-heading has-text-align-left prawy-tytul-pulpit\" style=\"margin-top:0px;margin-bottom:8px;font-style:normal;font-weight:600;line-height:1.2\">Getting Started with KanBo<\/h3><p class=\"has-text-align-left prawy-tekst wp-block-paragraph\" style=\"margin-bottom:8px\">Explore KanBo Learn, your go-to destination for tutorials and educational guides, offering expert insights and step-by-step instructions to optimize.<\/p><p class=\"prawy-link has-text-color has-link-color wp-elements-02abac7c05b8b530fd3b1b7827aca587 wp-block-paragraph\" style=\"color:#1672bb;margin-bottom:32px;padding-top:8px;padding-bottom:8px;font-style:normal;font-weight:700;line-height:1.5\"><a href=\"https:\/\/learn.kanboapp.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">KanBo Learn Platform \u2192<\/a><\/p><h3 class=\"wp-block-heading has-text-align-left prawy-tytul-pulpit\" style=\"margin-top:0px;margin-bottom:8px;font-style:normal;font-weight:600;line-height:1.2\">DevOps Help<\/h3><p class=\"has-text-align-left prawy-tekst wp-block-paragraph\" style=\"margin-bottom:8px\">Explore Kanbo's DevOps guide to discover essential strategies for optimizing collaboration, automating processes, and improving team efficiency.<\/p><p class=\"prawy-link has-text-color has-link-color wp-elements-09306734556c91c46ae8064a30b664b3 wp-block-paragraph\" style=\"color:#1672bb;margin-bottom:32px;padding-top:8px;padding-bottom:8px;font-style:normal;font-weight:700;line-height:1.5\"><a href=\"https:\/\/help.kanboapp.com\/en\/devops\/\" target=\"_blank\" rel=\"noreferrer noopener\">KanBo Dev Portal \u2192<\/a><\/p><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":3013,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-71287","page","type-page","status-publish","hentry"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\r\n<title>Navigating the Complexities of Risk Visibility: Transforming Pharmaceutical Risk Management Amidst Regulatory Competitive and Technological Challenges - KanBo<\/title>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/\" \/>\r\n<meta property=\"og:locale\" content=\"en_US\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"Navigating the Complexities of Risk Visibility: Transforming Pharmaceutical Risk Management Amidst Regulatory Competitive and Technological Challenges - KanBo\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/\" \/>\r\n<meta property=\"og:site_name\" content=\"KanBo\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"18 minutes\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/industries\\\/pharmaceutical\\\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\\\/\",\"url\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/industries\\\/pharmaceutical\\\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\\\/\",\"name\":\"Navigating the Complexities of Risk Visibility: Transforming Pharmaceutical Risk Management Amidst Regulatory Competitive and Technological Challenges - KanBo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/#website\"},\"datePublished\":\"2025-09-18T10:01:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/industries\\\/pharmaceutical\\\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kanboapp.com\\\/en\\\/industries\\\/pharmaceutical\\\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/industries\\\/pharmaceutical\\\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Industries\",\"item\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/industries\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"KanBo for Pharmaceutical\",\"item\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/industries\\\/pharmaceutical\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Navigating the Complexities of Risk Visibility: Transforming Pharmaceutical Risk Management Amidst Regulatory Competitive and Technological Challenges\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/\",\"name\":\"KanBo\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/#organization\",\"name\":\"KanBo\",\"url\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/kanboapp.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/image-122.png\",\"contentUrl\":\"https:\\\/\\\/kanboapp.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/image-122.png\",\"width\":196,\"height\":52,\"caption\":\"KanBo\"},\"image\":{\"@id\":\"https:\\\/\\\/kanboapp.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Navigating the Complexities of Risk Visibility: Transforming Pharmaceutical Risk Management Amidst Regulatory Competitive and Technological Challenges - KanBo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/","og_locale":"en_US","og_type":"article","og_title":"Navigating the Complexities of Risk Visibility: Transforming Pharmaceutical Risk Management Amidst Regulatory Competitive and Technological Challenges - KanBo","og_url":"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/","og_site_name":"KanBo","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"18 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/","url":"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/","name":"Navigating the Complexities of Risk Visibility: Transforming Pharmaceutical Risk Management Amidst Regulatory Competitive and Technological Challenges - KanBo","isPartOf":{"@id":"https:\/\/kanboapp.com\/en\/#website"},"datePublished":"2025-09-18T10:01:00+00:00","breadcrumb":{"@id":"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/navigating-the-complexities-of-risk-visibility-transforming-pharmaceutical-risk-management-amidst-regulatory-competitive-and-technological-challenges\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kanboapp.com\/en\/"},{"@type":"ListItem","position":2,"name":"Industries","item":"https:\/\/kanboapp.com\/en\/industries\/"},{"@type":"ListItem","position":3,"name":"KanBo for Pharmaceutical","item":"https:\/\/kanboapp.com\/en\/industries\/pharmaceutical\/"},{"@type":"ListItem","position":4,"name":"Navigating the Complexities of Risk Visibility: Transforming Pharmaceutical Risk Management Amidst Regulatory Competitive and Technological Challenges"}]},{"@type":"WebSite","@id":"https:\/\/kanboapp.com\/en\/#website","url":"https:\/\/kanboapp.com\/en\/","name":"KanBo","description":"","publisher":{"@id":"https:\/\/kanboapp.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kanboapp.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kanboapp.com\/en\/#organization","name":"KanBo","url":"https:\/\/kanboapp.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kanboapp.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/kanboapp.com\/wp-content\/uploads\/2023\/04\/image-122.png","contentUrl":"https:\/\/kanboapp.com\/wp-content\/uploads\/2023\/04\/image-122.png","width":196,"height":52,"caption":"KanBo"},"image":{"@id":"https:\/\/kanboapp.com\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/kanboapp.com\/en\/wp-json\/wp\/v2\/pages\/71287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kanboapp.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/kanboapp.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/kanboapp.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/kanboapp.com\/en\/wp-json\/wp\/v2\/comments?post=71287"}],"version-history":[{"count":0,"href":"https:\/\/kanboapp.com\/en\/wp-json\/wp\/v2\/pages\/71287\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/kanboapp.com\/en\/wp-json\/wp\/v2\/pages\/3013"}],"wp:attachment":[{"href":"https:\/\/kanboapp.com\/en\/wp-json\/wp\/v2\/media?parent=71287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}